natgillin/translations-raw huggingface dataset:
in whom hypoglycaemia develops gradually,
e jim hipoglikemija razvije počasi,
in whom hypoglycaemia develops gradually,
ki se jim hipoglikemija razvije počasi,
In women 27- through 45 years of age, efficacy of Gardasil 9 for the 4 original types is expected based on (1) high efficacy of qHPV vaccine in women 16- through 45 years of age and (2) comparable immunogenicity of Gardasil 9 and qHPV vaccine in girls and women 9- through 26 years of age.
Pri ženskah, starih od 27 do 45 let, pričakovana učinkovitost cepiva Gardasil 9 proti štirim prvotnim tipom temelji na (1) visoki učinkovitosti qHPV cepiva pri ženskah, starih od 27 do 45 let, in na (2) podobni imunogenosti cepiva Gardasil 9 in qHPV cepiva pri ženskah, starih od 9 do 26 let.
In women aged 18 to 35, the Pearl Index was around 0.4 with Ioa and 0.8 with the comparator medicine in the first study, and around 1.2 with Ioa and 1.9 with the comparator medicine in the second study.
Pri ženskah v starosti od 18 do 35 let je znašal Pearlov indeks v prvi študiji približno 0,4 z zdravilom Zoely in 0,8 s primerjalnim zdravilom, v drugi študiji pa približno 1,2 z zdravilom Zoely in 1,9 s primerjalnim zdravilom.
In women in pre-term labour receiving atosiban by infusion (300 micrograms/min for 6 to 12 hours), steady state plasma concentrations were reached within one hour following the start of the infusion (mean 442 ± 73 ng/ml, range 298 to 533 ng/ml).
Pri ženskah s prezgodnjim porodom, ki so dobile infuzijo atosibana (300 mikrogramov/min od 6 do12 ur), so bile plazemske koncentracije v stanju dinamičnega ravnovesja dosežene v eni uri po začetku infuzije (povprečno 442 ± 73 ng/ml, razpon od 298 do 533 ng/ml).
In women receiving darunavir/ritonavir 800/100 mg once daily during the second trimester of pregnancy, mean intra-individual values for total darunavir Cmax, AUC12h and Cmin were 34%, 34% and
Pri ženskah, ki so med drugim trimesečjem nosečnosti prejemale zdravili darunavir/ritonavir v odmerkih 800/100 mg enkrat na dan, so bile med posameznicami povprečne vrednosti celokupnega darunavirja Cmax, AUC12h in Cmin za 34%, 34% oziroma 32% manjše kot v obdobju po porodu.
In women receiving etravirine 200 mg b.i.d., higher mean values for Cmax, AUC12h and Cmin were observed during pregnancy compared to postpartum.
Pri ženskah, ki so prejemale 200 mg etravirina b.i.d. so med nosečnostjo opazili večje vrednosti Cmax, AUC12h in Cmin kot v obdobju po porodu.
In women receiving etravirine 200 mg b.i.d., higher mean values for Cmax, AUC12h and Cmin were observed during pregnancy compared to postpartum.
Pri ženskah, ki so prejemale 200 mg etravirina b.i.d., so med nosečnostjo opazili večje vrednosti Cmax, AUC12h in Cmin kot v obdobju po porodu.
In women undergoing assisted reproduction techniques, including in vitro fertilisation (IVF) and other methods, Fertavid can bring about the development of multiple follicles.
Pri ženskah, ki so v postopku oploditve z biomedicinsko pomočjo, vključno z zunajtelesno oploditvijo (IVF – in vitro fertilisation) in drugimi metodami, zdravilo Fertavid lahko povzroči razvoj večkratnih foliklov.
In women undergoing assisted reproduction techniques, including in vitro fertilisation (IVF) and other methods, Puregon can bring about the development of multiple follicles.
Pri ženskah, ki so v postopku oploditve z biomedicinsko pomočjo, vključno z zunajtelesno oploditvijo (IVF – in vitro fertilisation) in drugimi metodami, zdravilo Puregon lahko povzroči razvoj večkratnih foliklov.
In women who have been through the menopause Prolia reduces the risk of fractures in the spine and elsewhere in the body, including in the hip.
Pri ženskah po menopavzi zdravilo Prolia zmanjšuje tveganje za zlome hrbtenice in drugih kosti v telesu, vključno s kolkom.
In women who have been through the menopause, levels of the sex hormone oestrogen fall.
Pri ženskah po menopavzi upadejo ravni spolnega hormona estrogena.
In women whose endogenous gonadotrophin secretion is suppressed, follitropin alfa has nevertheless been shown to effectively stimulate follicular development and steroidogenesis, despite unmeasurable LH levels.
Pri ženskah z zavrtim izločanjem endogenega gonadotropina se je izkazalo, da folitropin alfa učinkovito spodbuja razvoj foliklov in steroidogenezo, kljub nemerljivim ravnem LH.
In women with an intact uterus, the risk of endometrial hyperplasia and carcinoma is increased when oestrogens are administered alone for prolonged periods.
Pri ženskah z nepoškodovano maternico se pri dolgotrajni uporabi samih estrogenov zveča tveganje za hiperplazijo in karcinom endometrija.
In women with baseline femoral neck BMD  -2.5, Prolia reduced the risk of non-vertebral fracture (35% relative risk reduction, 4.1% absolute risk reduction, p < 0.001, exploratory analysis).
Pri ženskah, ki so imele izhodiščno mineralno kostno gostoto stegneničnega vratu  –2,5, je zdravilo Prolia zmanjšalo tveganje nevretenčnih zlomov (35 % relativno zmanjšanje tveganja; 4,1 % absolutno zmanjšanje tveganja, p < 0,001, eksploratorna analiza).
In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema.
Pri ženskah z dednim angioedemom lahko eksogeni estrogeni sprožijo ali poslabšajo simptome angioedema.
In women with hereditary angioedema, exogenous oestrogens may induce or exacerbate symptoms of angioedema.
Pri ženskah z dednim angioedemom lahko eksogeni estrogeni sprožijo ali poslabšajo simptome angioedema.
In women with no personal history of VTE but with a first-degree relative with a history of thrombosis at young age, screening may be offered after careful counselling regarding its limitations (only a proportion of thrombophilic defects are identified by screening).
Ženskam, ki nimajo VTE v osebni anamnezi, vendar imajo sorodnika v prvem kolenu z anamnezo tromboze v zgodnji starosti, se lahko predlaga presejalni pregled po temeljitem svetovanju o omejitvah takšnega testiranja (pri presejalnih pregledih se odkrije le del trombofiličnih okvar).
In women with osteoporosis who had been through the menopause, Prolia was more effective than placebo at reducing fractures.
Pri ženskah z osteoporozo v obdobju po menopavzi je bilo zdravilo Prolia učinkovitejše od placeba pri zmanjševanju števila zlomov.
In women with recent or ongoing thromboembolic disease or women with generally recognised risk factors for thrombo-embolic events, such as personal or family history, treatment with gonadotropins may further increase the risk for aggravation or occurrence of such events.
Pri ženskah z nedavnimi ali potekajočimi trombemboličnimi boleznimi ali pri ženskah s splošno znanimi dejavniki tveganja za trombembolične dogodke, kot so osebna ali družinska anamneza, lahko zdravljenje z gonadotropini še poveča tveganje za poslabšanje ali pojav teh dogodkov.
In women, circulating testosterone is primarily bound in the serum to SHBG (65-80 %) and to albumin (20-30 %) leaving only about 0.5-2 % as the free fraction.
Pri ženskah je testosteron v krvnem obtoku vezan v serumu prvotno na SHBG (65–80%) in albumin (20–30%), delež prostega testosterona pa je le približno 0,5–2%.
In women, FSH is needed for the growth and development of the sacs (follicles) in the ovaries that contain the egg cells.
Pri ženskah je FSH potreben za rast in razvoj vrečk (foliklov) v jajčnikih, ki vsebujejo jajčeca.
In women, incidence rates for arthritis and arthralgia are generally higher than those seen in children (12 to 20%), and the reactions tend to be more marked and of longer duration.
Pri ženskah so pojavne stopnje artritisa in artralgije na splošno večje kot pri otrocih (12 do 20 %), neželeni učinki pa so izrazitejši in trajajo dalj časa.
In years 4 through 10, the rates of new vertebral and non-vertebral fractures did not increase over time; annualised rates were approximately 1.0% and 1.3% respectively.
V letih od 4 do 10 se stopnji novih vretenčnih in nevretenčnih zlomov sčasoma nista zvišali; na letni ravni je bil delež novih vretenčnih zlomov približno 1,0 % in delež novih nevretenčnih zlomov približno 1,3 %.
In young adult cattle and pig studies, gamithromycin was administered by injection at 6, 18, and 30 mg/kg (1, 3, and 5 times the recommended dose) and repeated three times at 0, 5 and 10 days (three times the recommended duration of use).
V študiji na mladem odraslem govedu in študijah na prašičih, so injicirali 6, 18 in 30 mg/kg gamitromicina (1, 3 in 5-kraten priporočen odmerek zdravila) in dajanje ponovili trikrat pri 0, 5 in 10 dneh (tri-kratno priporočeno trajanje zdravljenja).
In young children and toddlers (ages 12 to 23 months) receiving caspofungin at 50 mg/m2 daily (maximum 70 mg daily), the caspofungin plasma AUC0-24 hr after multiple doses was comparable to that seen in adults receiving caspofungin at 50 mg daily and to that in older children (2 to 11 years of age) receiving the 50 mg/m2 daily dose.
Pri malih otrocih (starih od 12 do 23 mesecev), ki so dobivali kaspofungin v odmerku 50 mg/m2 na dan (največ 70 mg na dan), je bila AUC0-24h kaspofungina v plazmi po večkratnih odmerkih primerljiva kot pri odraslih, ki so dobivali 50 mg kaspofungina na dan, in kot pri starejših otrocih (starih od 2 do 11 let), ki so dobivali dnevni odmerek 50 mg/m2.
In young pigs weighing approximately 10 kg given three or five times the therapeutic dose transient signs attributed to injection site discomfort were observed and included excessive vocalisation and restlessness.
Pri mladih prašičih s telesno težo okoli 10 kg, ki so prejeli trikraten oziroma petkraten terapevtski odmerek, so bili opaženi prehodni znaki, vezani predvsem na moteč občutek na mestu vbrizgavanja, glasno oglašanje in nemir.
In young subjects, Dynastat 40 mg twice daily had no clinically significant effect on acetylsalicylic acid - mediated inhibition of platelet function (see section 4.5).
Pri mladih preiskovancih zdravilo Dynastat v odmerku 40 mg dvakrat na dan ni klinično pomembno vplivalo na zavrtje delovanja trombocitov z acetilsalicilno kislino (glejte poglavje 4.5).
In younger children, two injections are given (at an interval of at least two months), except in infants aged between two and five months who receive three injections (at intervals of at least one month).
Mlajši otroci prejmejo dve injekciji (v razmiku vsaj dveh mesecev), razen dojenčki, stari od dva do pet mesecev, ki prejmejo tri injekcije (v razmiku vsaj enega meseca).
In younger patients aged 2-5 years absorption, based on Cmax values, was higher compared to adults.
Pri mlajših bolnikih od 2 – 5 let je bila absorbcija, na podlagi vrednosti Cmax, višja v primerjavi z odraslimi.
In younger patients, the most common side effects (seen in between 1 and 10 in 100 patients) are upper respiratory tract infections, ear infection, blood in the urine and fever.
Pri mlajših bolnikih so najpogostejši neželeni učinki (opaženi pri približno 1 do 10 bolnikov od 100) okužbe zgornjih dihal, kri v urinu in povišana telesna temperatura.
In your body
< - V vašem telesu
In your body
V vašem telesu
In your brain
< - V vaših možganih
In your brain
V vaših možganih
in your brain in your abdomen, lungs or in the membrane surrounding the heart
krvavitvami v možganih krvavitvami v trebuhu, pljučih ali ovojnici, ki obdaja srce
in your brain or in your spinal column
krvavitvami v možganih ali hrbtenjači
in your eyes
krvavitvami v očeh
in your eyes
v očeh
in your eyes and bruise of the eyes
krvavitvami v očeh in podplutbami v očeh
In your first treatment cycle, you may be treated every day up to 50 days at most or until your doctor determines that your disease is better.
V prvem ciklusu zdravljenja boste prejemali zdravilo največ 50 dni ali dokler zdravnik ne določi, da se je vaše stanje izboljšalo.
in your mouth or blood in your spit when coughing
krvavitvami v ustih in krvjo v izkašljani vsebini
in your stomach, bowel or dark/black blood in the stools
krvavitvami v želodcu, črevesju ali temno/črno krvjo v blatu
In, study MDS-003, in which 148 patients received lenalidomide at a dose of 10 mg, the primary efficacy analysis consisted of an evaluation of the efficacy of lenalidomide treatments to achieve haematopoietic improvement in subjects with low- or intermediate-1 risk myelodysplastic syndromes.
V študiji MDS-003, v kateri je 148 bolnikov prejemalo lenalidomid v odmerku 10 mg, je analizo primarne učinkovitosti predstavljalo ovrednotenje učinkovitosti zdravljenja z lenalidomidom za doseganje hematopoetskega izboljšanja pri preskušancih z mielodisplastičnimi sindromi z majhnim ali srednjim-1 tveganjem.
In-circuit oxygen meters can be used to measure the inspired oxygen fraction and depending on the individual animal, a level of 50 – 100 % of the veterinary medicinal product may be required.
Za merjenje vdihnjenega deleža kisika se lahko uporabi merilce kisika, s katerimi se lahko, glede na potrebe posamezne živali določi stopnjo potrebnega zdravila med 50 - 100 % .
In-feed use
Dajanje v krmno mešanico.
In-feed use
V krmno mešanico
In-feed use
V krmno mešanico.
In-feed use for rabbits:
Dajanje v krmni mešanici za kunce:
In-feed use.
V krmno mešanico.
In-feed use.
Za krmno mešanico.
In-line filters must not be used when administering DepoCyte.
Pri dajanju zdravila DepoCyte ne smete uporabljati filtrov za linije za infundiranje.
In-line filters must not be used when administering DepoCyte.
Pri dajanju zdravila DepoCyte ne uporabljajte in-line filtrov.
In-ovo equipment should be calibrated to ensure that a 0.05 ml dose is applied to each egg.
In-ovo naprave morajo biti kalibrirane, da se zagotovi odmerek 0,05 ml na vsako jajce.
In-ovo route:
In-ovo dajanje:
In-use cartridges
Injekcijski peresniki, ki jih uporabljate
In-use cartridges
Odprt vložek
In-use cartridges
Vložki, ki jih uporabljate
In-use cartridges
Vložki, ki jih uporabljate.
In-use cartridges
Vložki, ki jih uporabljate:
In-use cartridges
Vložki, ki so v uporabi
In-use cartridges:
Vložki, ki jih uporabljate
In-use OptiSet, a dose of 2 units has to be selected by turning the dosage selector forward till the dose arrow points to 2.
Pri OptiSetu, ki ga bolnik uporablja, naj izbere odmerek 2 enoti tako, da izbirnik odmerka zavrti naprej, dokler odmerna puščica ne pokaže 2.
In-use OptiSet, a dose of 2 units has to be selected by turning the dosage selector forward till the dose arrow points to 2.
Pri OptiSetu, ki ga bolnika uporablja, naj izbere odmerek 2 enoti tako, da izbirnik odmerka zavrti naprej, dokler odmerna puščica ne pokaže 2.
In-use OptiSet, a dose of 2 units has to be selected by turning the dosage selector forward till the dose arrow points to 2.
Pri OptiSetu, ki ga uporabljate, izberite odmerek 2 enoti tako, da izbirnik odmerka zavrtite naprej, dokler odmerna puščica ne pokaže 2.
In-use OptiSet: select a dose of 2 units by turning the dosage selector forward till the dose arrow points to 2.
OptiSet, ki ga uporabljate: nastavite odmerek 2 enoti tako, da izbirnik odmerka zavrtite naprej, dokler odmerna puščica ne kaže 2.
In-use Pen
Peresnik, ki je v uporabi
In-use pens
Peresniki, ki so v uporabi
In-use pens
Uporabljeni injekcijski peresniki
In-use shelf life
Rok uporabnosti med uporabo
In-use shelf life after 1st opening:
Rok uporabnosti po prvem odpiranju:
In-use shelf life after 1st opening:
Rok uporabnosti po prvem odpiranju;
In-use shelf life after mixing: 2 hours.
Rok uporabnosti po mešanju: 2 uri.
In-use shelf life: 2 months
Rok uporabnosti po prvem odprtju: 2 meseca
In-use shelf life: 2 months
Rok uporabnosti po prvem odprtju: 2 meseca.
In-use shelf life: 30 days.
Rok uporabnosti po odprtju: 30 dni.
In-use shelf-life after opening the tray: 6 weeks
Rok uporabnosti po prvem odprtju: 6 tednov.
In-use stability after first opening and/or dilution: from a microbiological point of view, after dilution, the reconstituted medicinal product should be used immediately.
Stabilnost po prvem odprtju in/ali redčenju: z mikrobiološkega stališča je treba rekonstituirano zdravilo uporabiti takoj po redčenju.
In-use stability demonstrated for 3 hours at 2- 8 °C.
Stabilnost med uporabo je dokazana za 3 ure pri temperaturi od 2 do 8 °C.
In-use stability demonstrated for 3 hours at 2- 8°C.
Stabilnost med uporabo je dokazana za 3 ure pri temperaturi od 2 do 8 °C.
In-use stability demonstrated for 3 hours at 2-8 °C.
Stabilnost med uporabo je dokazana za 3 ure pri temperaturi od 2 do 8 °C.
In-use stability has been demonstrated for 2 days at 2 °C – 8 °C.
Stabilnost med uporabo so dokazali za 2 dni pri 2 °C - 8 °C.
In-use stability shelf-life: Unused Siklos 1000 mg broken tablets must be replaced in the bottle and must be used within three months”
Rok uporabnosti in stabilnost v času uporabe: neuporabljene zlomljene tablete zdravila Siklos 1000 mg morate shraniti nazaj v plastenko in uporabiti v roku treh mesecev.
In-use stability: Chemical and physical in-use stability after dilution has been demonstrated for 24 hours at 2 – 8 °C and 25 °C.
Stabilnost med uporabo: dokazana je bila 24-urna kemična in fizična stabilnost razredčenega zdravila pri 2–8 °C in 25 °C.
In-use storage times and conditions should not exceed 2 hours at room temperature (15 °C – 30 °C).
Čas in pogoji shranjevanja zdravila, ki se ne uporabi takoj, ne sme biti daljši kot 2 ure pri sobni temperaturi (15 °C do 30 °C).
In-use tube: 7 days.
Tuba, ki je v uporabi: 7 dni.
In-vitro activity against these pathogens as well as against other skin and urinary tract pathogens collected during a European (Denmark, France, Germany, Italy and United Kingdom) MIC survey (1999 – 2000) and during European (France, Germany, Spain and United Kingdom) clinical efficacy and safety field studies (2001 – 2003) are listed below.
In-vitro učinkovitost proti tem patogenom kot tudi proti ostalim patogenom kože in urinarnega trakta, ki so bili zbrani med evropskim (Danska, Francija, Nemčija, Italija in Velika Britanija) MIC pregledom (1999 – 2000) ter med evropskimi (Francija, Nemčija, Španija in Velika Britanija) kliničnimi študijami glede učinkovitosti in varnosti (2001 – 2003), je predstavljena v spodnji preglednici.
In-vitro experiments demonstrated that P-glycoprotein efflux does not occur, confirming that afoxolaner is not a substrate for the
In-vitro študije so dokazale, da ne pride do iztoka P-glikoproteinov, kar potrjuje, da afoksolaner ni substrat za P-glikoproteinski transport.
In-vitro studies in human liver microsomes indicate that ertapenem does not inhibit metabolism mediated by any of the six major CYP isoforms: 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4.
In vitro študije človeških jetrnih mikrosomov kažejo, da ertapenem ne zavira presnove z nobeno od šestih glavnih izooblik CYP: 1A2, 2C9, 2C19, 2D6, 2E1 in 3A4.
In-vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.
Raziskave in vitro kažejo, da ertapenem ne zavira s P-glikoproteinom posredovanega transporta digoksina ali vinblastina in da ertapenem ni substrat za s P-glikoproteinom posredovani transport.
In-vitro studies indicate that the effect of ertapenem on the plasma protein binding of highly protein bound medicinal products (warfarin, ethinyl estradiol, and norethindrone) was small.
V študijah in vitro je bil vpliv ertapenema na vezavo zdravil, ki se močno vežejo na plazemske beljakovine (varfarin, etinilestradiol in noretindron), majhen.
In-vitro studies showed that delamanid and metabolites did not have any effect on the transporters MDR1(p- gp), BCRP, OATP1, OATP3, OCT1, OCT2, OATP1B1, OATP1B3 and BSEP, at concentrations of approximately 5 to 20 fold greater than the Cmax at steady state.
V študijah in-vitro so opazili, da delamanid in presnovki niso vplivali na prenašalce MDR1 (p-gp), BCRP, OATP1, OATP3, OCT1, OCT2, OATP1B1, OATP1B3 in BSEP, pri koncentracijah, približno 5- do 20-krat višjih kot Cmax v stanju dinamičnega ravnovesja.
In-vivo and ex-vivo animal studies have demonstrated antithrombotic efficacy and anticoagulant activity of dabigatran after intravenous administration and of dabigatran etexilate after oral administration in various animal models of thrombosis.
Raziskave na živalih in vivo ter ex vivo so na različnih živalskih modelih tromboze pokazale, da delujeta dabigatran po intravenskem in dabigatran eteksilat po peroralnem vnosu antitrombotično in antikoagulacijsko.
In-vivo: Inhibition of osteoclastic bone resorption, which alters the bone marrow microenvironment, making it less conducive to tumour cell growth, anti-angiogenic activity and anti-pain activity.
In vivo: Inhibicijo osteoklastne resorpcije kosti, ki spremeni mikrookolje kostnega mozga, tako da je le-to manj ugodno za rast tumorskih celic, protiangiogeno aktivnost in protibolečinsko aktivnost.
Inability for your eye to sense pain (anaesthesia of the cornea or conjunctiva or hypoaesthia)
nezmožnost zaznavanja bolečine v očesu (anestezija ali hipestezija roženice ali veznice);
Inability of the body to respond normally to severe stress such as accidents, surgery or illness due to insufficient function of the adrenal glands, severe unusual headache with visual disturbances linked to the withdrawal of treatment, irregularity of menstrual cycles in women;
nezmožnost telesa, da bi se normalno odzvalo na velik stres, kot so nesreče, operacija ali bolezen, zaradi nezadostnega delovanja nadledvične žleze, hud neobičajen glavobol z motnjami vida, ki je povezan s prekinitvijo zdravljenja, neredni menstruacijski ciklusi pri ženskah;
Inability of the heart to maintain adequate blood circulation.
nezmožnost srca vzdrževati primeren krvni obtok
Inability of the heart to pump enough blood round the body (heart failure);
nezmožnost srca, da bi črpalo dovolj krvi po telesu (srčno popuščanje);
inability of the liver
okvarjeno delovanje jeter
Inability to achieve full adult height may occur in some children and adolescents
Nezmožnost doseganja popolne odrasle višine pri nekaterih otrocih in mladostnikih.
inability to achieve or maintain an erection
nezmožnost doseganja ali vzdrževanja erekcije
Inability to control your bowel movements.
nezmožnost nadzirati iztrebljanje
inability to control your bowels;
nezmožnost kontrole črevesa;
inability to control your bowels;
nezmožnost nadzorovanja črevesa;
Inability to develop or maintain an erection
nezmožnost doseganja in vzdrževanja erekcije;
inability to develop or maintain an erection chills, flu-like illness
nezmožnost doseči ali ohraniti erekcijo mrzlica, gripi podobna bolezen
inability to either stand or walk in a normal manner
nezmožnost normalnega stanja ali hoje
inability to fall asleep or stay asleep
nezmožnost zaspati ali zbujanje ponoči,
inability to get or maintain an erection
nezmožnost erekcije ali ohranjanja erekcije,
Inability to heal properly.
nezmožnost ustreznega celjenja
inability to pass urine
nezmožnost odvajanja urina
Inability to pass urine.
nezmožnost odvajanja urina,
inability to pass water (urinate) fever
nezmožnost odvajanja vode (uriniranja) zvišana telesna temperatura
Inability to produce enough insulin or resistance to normal levels of insulin
nezmožnost tvorbe insulina ali odpornost na normalne koncentracije insulina
inability to reach orgasm
nezmožnost orgazma
Inability to resist the impulse to perform an action that could be harmful, which may include:
nezmožnost upiranja nagibom za izvajanje dejavnosti, ki so lahko škodljive in lahko vključujejo:
Inability to resist the impulse to perform an action that could be harmful, which may include:
nezmožnost, da bi se uprli težnji, da storite nekaj, kar lahko škodi vam ali drugim, kar lahko vključuje:
inability to resist the impulse to perform an action that is harmful involving excessive gambling, repetitive meaningless actions, binge eating, compulsive eating and compulsive shopping swelling of legs and feet
nezmožnost upreti se impulzu po opravljanju določenih škodljivih dejavnosti, vključno s pretiranim hazardiranjem, ponavljanjem nesmiselnih dejanj, prenajedanjem, kompulzivnim prehranjevanjem in kompulzivnim nakupovanjem zatekanje nog in stopal
Inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include:
nezmožnost upreti se impulzu, težnji ali skušnjavi po dejanjih, ki bi lahko škodila vam ali drugim, kot so: